In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Edwards Lifesciences trading 34% above a high-confidence fair value of $70.73 signals potential overvaluation risk. Monte Carlo results show a 94.4% chance of downside below the current price, with wide volatility (62.12% CV), underscoring elevated uncertainty. Strong liquidity and leverage contrast with moderate profitability and growth scores.